China Resources Double-Crane Pharmaceutical announced that its wholly-owned subsidiary, China Resources Saike Pharmaceutical Co., Ltd., has received the "Drug Supplementary Application Approval Notice" for Amlodipine Atorvastatin Calcium Tablets issued by the National Medical Products Administration. This drug is suitable for patients requiring a combination treatment of amlodipine and atorvastatin, with a specification of 5mg/20mg. The cumulative research and development investment is RMB 9.4074 million. In 2023, the total sales of Amlodipine Atorvastatin Calcium Tablets in the domestic medical market amounted to RMB 0.647 billion, with sales revenue of RMB 5.5281 million for China Resources Saike Pharmaceutical Co. This approval will be beneficial for future market sales and competition.